Long acting insulin for reducing cardiovascular morbidity and mortality in prediabetic patents and patients with Type 2 diabetes

摘要

This invention relates to a method of reducing cardiovascular morbidity and mortality in a prediabetic or Type 2 Diabetes patient population. The method comprises administering an effective dosage of a long acting insulin, preferably insulin glargine, to a prediabetic or Type 2 Diabetes patient.